Literature DB >> 11444765

The economic and social burden of depression.

N Sartorius1.   

Abstract

Depressive disorders are a major public health problem. They occur frequently and produce severe suffering for those affected and for their families. They are ubiquitous and appear at all ages. The consequences of depressive disorders in terms of excessive mortality, disability, and secondary morbidity are grave. There are indications that the frequency of depressive disorders will increase in the years to come, for a variety of reasons, including demographic changes, extended life expectancy of people suffering from chronic physical disorders, and iatrogenic causes. The essential criterion for designating a condition as a major public health problem--that there should be an effective intervention that will diminish or eliminate the problem-has now also been met. Recent years have seen the development of a variety of new treatments that can be applied even in situations where highly specialized mental health staff are scarce. These developments make training in the use of new treatment methods of proven value and their wide application a public health priority and an ethical obligation. The presentation will discuss these issues on the basis of accumulated evidence and experience.

Entities:  

Mesh:

Year:  2001        PMID: 11444765

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  32 in total

Review 1.  Adolescent-Onset Depression: Are Obesity and Inflammation Developmental Mechanisms or Outcomes?

Authors:  Michelle L Byrne; Neil M O'Brien-Simpson; Sarah A Mitchell; Nicholas B Allen
Journal:  Child Psychiatry Hum Dev       Date:  2015-12

2.  Blunted amygdala activity is associated with depression severity in treatment-resistant depression.

Authors:  Jamie Ferri; Stuart J Eisendrath; Susanna L Fryer; Erin Gillung; Brian J Roach; Daniel H Mathalon
Journal:  Cogn Affect Behav Neurosci       Date:  2017-12       Impact factor: 3.282

3.  Premorbid risk factors for major depressive disorder: are they associated with early onset and recurrent course?

Authors:  Sylia Wilson; Uma Vaidyanathan; Michael B Miller; Matt McGue; William G Iacono
Journal:  Dev Psychopathol       Date:  2014-11

4.  Beneficial effects of adjunctive aripiprazole in major depressive disorder are not dependent on antidepressant therapy history: a post hoc analysis of 3 randomized, double-blind, placebo-controlled trials.

Authors:  David L Dunner; Kimberly K Laubmeier; George Manos; Robert A Forbes; Ross A Baker; Robert M Berman
Journal:  Prim Care Companion CNS Disord       Date:  2012-11-22

5.  Worsening trends in adult health-related quality of life and self-rated health-United States, 1993-2001.

Authors:  Matthew M Zack; David G Moriarty; Donna F Stroup; Earl S Ford; Ali H Mokdad
Journal:  Public Health Rep       Date:  2004 Sep-Oct       Impact factor: 2.792

Review 6.  Blood-based biomarkers predicting response to antidepressants.

Authors:  Yasmin Busch; Andreas Menke
Journal:  J Neural Transm (Vienna)       Date:  2018-01-27       Impact factor: 3.575

7.  Sustainable effects on suicidality were found for the Nuremberg alliance against depression.

Authors:  Ulrich Hegerl; Roland Mergl; Inga Havers; Armin Schmidtke; Hartmut Lehfeld; Günter Niklewski; David Althaus
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11-17       Impact factor: 5.270

8.  Prospective inter-relationships between late adolescent personality and major depressive disorder in early adulthood.

Authors:  S Wilson; A C DiRago; W G Iacono
Journal:  Psychol Med       Date:  2013-05-20       Impact factor: 7.723

9.  Social capital elite, excluded participators, busy working parents and aging, participating less: types of community participators and their mental health.

Authors:  Helen Louise Berry
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-03-22       Impact factor: 4.328

10.  Patterns of psychosocial risk and long-term outcomes in rheumatoid arthritis.

Authors:  Anne Morris; Edward H Yelin; Belinda Wong; Patricia P Katz
Journal:  Psychol Health Med       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.